Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells

• US 5,437,994 A
• Filed: 12/10/1993
• Issued: 08/01/1995
• Est. Priority Date: 06/15/1989
• Status: Expired due to Term

• Current Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Original Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Inventors: Palsson, Bernhard O., Clarke, Michael F., Emerson, Stephen G.
• Primary Examiner(s): Ziska, Suzanne E.
• Application Number:
  US08/164,779
• Time in Patent Office: 599 Days
• Field of Search: 435/172.3, 435/240.1, 435/240.2
• US Class Current: 435/373
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/535 Granulocyte CSF; Granulocyte-macrophage CSF
• CPC Class Codes: C07K 14/5403 IL-3
• CPC Class Codes: C07K 14/5412 IL-6
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C12N 15/85 for animal cells
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2501/125 Stem cell factor [SCF], c-kit ligand [KL]
• CPC Class Codes: C12N 2501/14 Erythropoietin [EPO]
• CPC Class Codes: C12N 2501/22 Colony stimulating factors (G-CSF, GM-CSF)
• CPC Class Codes: C12N 2501/23 Interleukins [IL]
• CPC Class Codes: C12N 2501/39 Steroid hormones
• CPC Class Codes: C12N 2502/1394 Bone marrow stromal cells; whole marrow
• CPC Class Codes: C12N 2502/99 genetically modified cells
• CPC Class Codes: C12N 2740/13043 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 5/0641 Erythrocytes
• CPC Class Codes: C12N 5/0642 Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
• CPC Class Codes: C12N 5/0647 Haematopoietic stem cells; Uncommitted or multipotent progenitors

Abstract

Methods, including culture media conditions, which provide for ex vivo human stem cell division and/or the optimization of human hematopoietic progenitor cell cultures and/or increasing the metabolism or GM-CSF secretion or IL-6 secretion of human stromal cells are disclosed. The methods rely on culturing human stem cells and/or human hematopoietic progenitor cells and/or human stromal cells in a liquid culture medium which is replaced, preferably perfused, either continuously or periodically, at a rate of 1 ml of medium per ml of culture per about 24 to about 48 hour period, and removing metabolic products and replenishing depleted nutrients while maintaining the culture under physiologically acceptable conditions. Optionally growth factors are added to the culture medium.

Claims

1. A method for obtaining ex vivo human stem cell division comprising culturing a human hematopoietic stem cell composition in a liquid culture medium which is replaced at a rate of from 50 to 100% daily replacement, while maintaining said culture under physiologically acceptable conditions.

2. The method of claim 1, wherein said medium is replaced continuously.

3. The method of claim 2, wherein replacement of said medium comprises perfusing fresh medium through at least part of the mass of said human hematopoietic stem cell composition.

4. The method of claim 1, wherein said medium is replaced periodically.

5. The method of claim 4, wherein replacement of said medium comprises perfusing fresh medium through at least part of the mass of said human hematopoietic stem cell composition.

6. The method of claim 1, wherein said culture medium contains at least one member selected from the group consisting of human peripheral blood mononuclear cells, human bone marrow cells, human fetal liver cells, and human cord blood cells.

7. The method of claim 6, wherein said human peripheral blood mononuclear cells, human bone marrow cells, human fetal liver cells, and human cord blood cells have been enriched for human hematopoietic stem cells.

8. The method of claim 1, wherein said cultured human hematopoietic stem cell composition produces human hematopoietic progenitor cells.

9. The method of claim 1, wherein IL-3 and GM-CSF are added continuously to said medium, each at a rate of 0.1 to 100 ng ml^-1 day^-1.

10. The method of claim 1, wherein IL-3 and GM-CSF are added continuously to said medium, each at a rate of 0.5 to 10 ng ml^-1 day^-1.

11. The method of claim 1, wherein steel factor is added to said medium.

12. The method of claim 1, wherein steel factor is added to said medium at a rate of 1 to 100 ng ml^-1 day^-1.

13. The method of claim 9, wherein Epo is added to said medium at a rate of 0.001 to 10 U ml^-1 day^-1, steel factor is added to said medium at a rate of from 1 to 100 ng ml^-1 day^-1, or IL-1 (α

or β

) is added to said medium at a rate of from 10 to 100 U ml^-1 per 3 to 5 day period.

14. The method of claim 1, wherein Epo is added to said medium at a rate of 0.001 to 10 U ml^-1 day^-1.

15. The method of claim 9, wherein Epo is added to said medium at a rate of 0.05 to 0.15 U ml^-1 day^-1.

16. The method of claim 13, wherein at least one member selected from the group consisting of G-CSF, basic fibroblast growth factor, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, PDGF and EGF, is added to said medium.

17. The method of claim 1, wherein said medium comprises animal sera or plasma.

18. The method of claim 1, wherein said medium comprises human sera or plasma.

19. The method of claim 1, wherein said medium comprises a corticosteroid.

20. The method of claim 1, comprising maintaining glucose concentration in said medium in the range of from 5 of 20 mM, lactate concentration in said medium below about 35 mM, glutamine concentration in said medium in the range of from 1 to 3 mM, and ammonia concentration in said medium below 2.5.

21. The method of claim 6, said culture comprising human bone marrow stromal cells in an amount of 10^-3 to 10^-1 (stromal cells/total cells).

30. The method of claim 21, wherein IL-3 and GM-CSF are added continuously to said medium, each at a rate of 0.1 to 100 ng ml^-1 day^-1.

43. The method of claim 6, wherein said medium contains human peripheral blood mononuclear cells.

44. The method of claim 6, wherein said medium contains human bone marrow cells.

45. The method of claim 6, wherein said medium contains human fetal liver cells.

46. The method of claim 6, wherein said medium contains human cord blood cells.

51. The method of claim 1, wherein said culture medium further comprises stromal cells.

22. A method for expanding and harvesting a human hematopoietic stem cell pool, comprising:

(i) culturing a human hematopoietic stem cell composition in a liquid culture medium which is replaced at a rate from 50 to 100% daily replacement, while maintaining said culture under physiologically acceptable conditions, to obtain an expanded human hematopoietic stem cell pool; and

(ii) harvesting said expanded human hematopoietic stem cell pool.

52. The method of claim 22, wherein said culture medium further comprises stromal cells.

23. A method for culturing a human hematopoietic progenitor cell composition comprising culturing human hematopoietic progenitor cells in a liquid culture medium which is replaced at a rate from 50 to 100% daily replacement, while maintaining said culture under physiologically acceptable conditions.

24. The method of claim 23, wherein said medium is replaced continuously.

25. The method of claim 24, wherein replacement of said medium comprises perfusing fresh medium through at least part of the mass of said human hematopoietic progenitor cell composition.

26. The method of claim 23, wherein said medium is replaced periodically.

27. The method of claim 26, wherein replacement of said medium comprises perfusing fresh medium through at least part of the mass of said human hematopoietic progenitor cell composition.

28. The method of claim 23, wherein at least one member selected from the group consisting of human peripheral blood mononuclear cells, human bone marrow cells, human fetal liver cells, and human cord blood cells, are cultured.

29. The method of claim 28, wherein said cells have been enriched for said human hematopoietic progenitor cells.

31. The method of claim 23, wherein IL-3 and GM-CSF are added continuously to said medium, each at a rate of 0.5 to 10 ng ml^-1 day^-1.

32. The method of claim 23, wherein steel factor is added to said medium.

33. The method of claim 23, wherein steel factor is added to said medium at a rate of 1 to 100 ng ml^-1 day^-1.

34. The method of claim 31, wherein Epo is added to said medium at a rate of 0.001 to 10 U ml^-1 day^-1, steel factor is added to said medium at a rate of from 1 to 100 ng ml^-1 day^-1, or I1^-1 (α

or β

) is added to said medium at a rate of from 10 to 100 U ml^-1 per 3 to 5 day period.

35. The method of claim 31, wherein Epo is added to said medium at a rate of 0.001 to 10 U ml^-1 day^-1.

36. The method of claim 31, wherein Epo is added to said medium at a rate of 0.05 to 0.15 U ml^-1 day^-1.

37. The method of claim 34, wherein at least one member selected from the group consisting of GM-CSF, basic fibroblast growth factor, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, PDGF and EGF, is added to said medium.

38. The method of claim 23, wherein said medium comprises animal sera or plasma.

39. The method of claim 23, wherein said medium comprises human sera or plasma.

40. The method of claim 23, wherein said medium comprises a corticosteroid.

41. The method of claim 23, comprising maintaining glucose concentration in said medium in the range of from 5 to 20 mM, lactate concentration in said medium below about 35 mM, glutamine concentration in said medium in the range of from 1 to 3 mM, and ammonia concentration in said medium below 2.5 mM.

42. The method of claim 35, wherein said human stromal cells are human bone marrow stromal cells.

47. The method of claim 28, wherein human peripheral blood mononuclear cells are cultured.

48. The method of claim 28, wherein human bone marrow cells are cultured.

49. The method of claim 28, wherein human fetal liver cells are cultured.

50. The method of claim 28, wherein human cord blood cells are cultured.

53. The method of claim 23, wherein said culture medium further comprises stromal cells.